1,894
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

, , , , , , , & ORCID Icon show all
Pages 871-879 | Received 20 Jul 2021, Accepted 16 Sep 2021, Published online: 13 Oct 2021

Figures & data

Figure 1. Planned accrual design. (a) Schema for sequential single-agent lead-in to doublet therapy. (b) Following a protocol amendment, sequential lead-in was eliminated and all patients were enrolled to doublet therapy upfront.

Figure 1. Planned accrual design. (a) Schema for sequential single-agent lead-in to doublet therapy. (b) Following a protocol amendment, sequential lead-in was eliminated and all patients were enrolled to doublet therapy upfront.

Figure 2. Enrollment. IF: informed consent; PI: principal investigator.

Figure 2. Enrollment. IF: informed consent; PI: principal investigator.

Table 1. Baseline patient characteristics.

Table 2. Best response by treatment arm and drug.

Table 3. Adverse events.